Aand leukemia berrantclinicalFLT3 (AML) managementreceptor and has signalingof important the disease.is implications commonPatientsinwith for acuteFLT3-mutat- the myeloid biology ed AML frequently present with critical illness, are more likely to relapse after treatment, and have worse clinical outcomes than their FLT3 wild-type counterparts. The clinical management of FLT3-mutated AML has been transformed by the development of FLT3 inhibitors, which are now in use in the frontline and relapsed/refractory settings. However, many questions regarding the optimal approach to the treatment of these patients remain. In this paper, we will review the rationale for targeting the FLT3 receptor in AML, the impact of FLT3 mutation on patient prognosis, the current standard of care approaches to FLT3-mutated AML management, and the diverse array of FLT3 inhibitors in use and under investigation. We will also explore new opportunities and strategies for targeting the FLT3 receptor. These include targeting the receptor in patients with non-canonical FLT3 mutations or wild-type FLT3, pairing FLT3 inhibitors with other novel therapies, using minimal residual disease testing to guide the targeting of FLT3, and novel immunotherapeutic approaches.
ASJC Scopus subject areas